BR112015010019A2 - benzimidazóis tricíclicos substituídos - Google Patents
benzimidazóis tricíclicos substituídosInfo
- Publication number
- BR112015010019A2 BR112015010019A2 BR112015010019A BR112015010019A BR112015010019A2 BR 112015010019 A2 BR112015010019 A2 BR 112015010019A2 BR 112015010019 A BR112015010019 A BR 112015010019A BR 112015010019 A BR112015010019 A BR 112015010019A BR 112015010019 A2 BR112015010019 A2 BR 112015010019A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- substituted tricyclic
- benzimidazoles
- diseases
- kinase
- Prior art date
Links
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 101150090188 Cdk8 gene Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 101150112625 SSN3 gene Proteins 0.000 abstract 2
- 101100150415 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srb10 gene Proteins 0.000 abstract 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000001441 melanoma Diseases 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
abstract disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (i) or pharmaceutically acceptable salts thereof. the compounds of the invention selectively inhibit cdk8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. also disclosed are processes for preparing these compounds. tradução do resumo resumo: patente de invenção para "benzimidazóis tricíclicos substituídos" descritos são os compostos de benzimidazóis tricíclicos substituídos como definido aqui na fórmula (i) ou sais farmaceuticamente aceitáveis dos mesmos. os compostos da invenção seletivamente inibem cdk8 e são, portanto, úteis para tratar doenças relacionadas a esta cinase, especialmente cânceres colorretal e melanoma e outras malignidades sólidas e hematológicas, doenças autoimunes e doenças inflamatórias. da mesma forma descritos são os processos para preparar estes compostos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1220157.0 | 2012-11-08 | ||
GBGB1220157.0A GB201220157D0 (en) | 2012-11-08 | 2012-11-08 | Substitute tricyclic benzimidazoles as kinase inhibitors |
PCT/EP2013/073311 WO2014072435A1 (en) | 2012-11-08 | 2013-11-07 | Substituted tricyclic benzimidazoles as kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015010019A2 true BR112015010019A2 (pt) | 2017-07-11 |
BR112015010019A8 BR112015010019A8 (pt) | 2019-09-17 |
BR112015010019B1 BR112015010019B1 (pt) | 2022-08-09 |
Family
ID=47470315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015010019-8A BR112015010019B1 (pt) | 2012-11-08 | 2013-11-07 | Benzimidazóis tricíclicos substituídos, seus usos, e composição farmacêutica |
Country Status (22)
Country | Link |
---|---|
US (1) | US9745299B2 (pt) |
EP (1) | EP2917217B1 (pt) |
JP (1) | JP6101812B2 (pt) |
KR (1) | KR101812390B1 (pt) |
CN (1) | CN104903321B (pt) |
AU (1) | AU2013343550B2 (pt) |
BR (1) | BR112015010019B1 (pt) |
CA (1) | CA2890643C (pt) |
CY (1) | CY1119084T1 (pt) |
DK (1) | DK2917217T3 (pt) |
ES (1) | ES2628046T3 (pt) |
GB (1) | GB201220157D0 (pt) |
HR (1) | HRP20170802T1 (pt) |
HU (1) | HUE033485T2 (pt) |
IL (1) | IL238693A0 (pt) |
LT (1) | LT2917217T (pt) |
MX (1) | MX363609B (pt) |
PL (1) | PL2917217T3 (pt) |
PT (1) | PT2917217T (pt) |
RS (1) | RS56056B1 (pt) |
SI (1) | SI2917217T1 (pt) |
WO (1) | WO2014072435A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3133075B1 (en) | 2014-04-18 | 2020-12-30 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
BR112018008931A8 (pt) | 2015-11-03 | 2019-02-26 | Lu License Ab | ?compostos para tratamento de distúrbios hipoproliferativos? |
JP7142846B2 (ja) | 2017-01-30 | 2022-09-28 | 国立大学法人京都大学 | 新規化合物及び制御性t細胞の製造方法 |
EP3591040A4 (en) * | 2017-03-03 | 2020-11-11 | Kyoto University | METHOD FOR PRODUCING PANCREATIC ANALYZER CELLS |
EP3607944A4 (en) * | 2017-04-03 | 2020-11-18 | Kyoto Pharmaceutical Industries, Ltd. | NEW INHIBITOR OF THE CYCLINE-DEPENDENT KINASE 8 AND / OR 19 |
US11261184B2 (en) | 2017-10-02 | 2022-03-01 | Boehringer Ingelheim International Gmbh | [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors |
WO2020038387A1 (zh) * | 2018-08-24 | 2020-02-27 | 杭州阿诺生物医药科技有限公司 | 高活性sting蛋白激动剂 |
EP3873896A4 (en) * | 2018-12-14 | 2022-08-31 | Jiangsu Hengrui Medicine Co., Ltd. | TRICYCLIC COMPOUNDS AS STING AGONISTS AND METHODS OF MANUFACTURE AND MEDICAL USES THEREOF |
EP4041236A4 (en) * | 2019-10-03 | 2023-10-25 | Dana-Farber Cancer Institute, Inc. | TRICYCLIC KINASE INHIBITORS AND THEIR USES |
CN111349094B (zh) * | 2020-04-23 | 2021-02-02 | 杭州师范大学 | 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用 |
TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
CN116391028A (zh) | 2020-11-20 | 2023-07-04 | 千纸鹤治疗公司 | 促熟剂 |
KR20230145101A (ko) | 2021-02-09 | 2023-10-17 | 오리즈루 세라퓨틱스 가부시키가이샤 | 성숙화제 |
TW202330910A (zh) | 2021-09-27 | 2023-08-01 | 國立大學法人京都大學 | T細胞的製造方法 |
US11970494B2 (en) | 2021-11-09 | 2024-04-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
WO2023241627A1 (en) * | 2022-06-15 | 2023-12-21 | Insilico Medicine Ip Limited | Cdk8/19 dual inhibitors and methods of use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2899757B2 (ja) | 1989-06-26 | 1999-06-02 | 持田製薬株式会社 | ジヒドロイミダゾキノリノンオキシムスルホン酸誘導体 |
US5500423A (en) * | 1994-09-09 | 1996-03-19 | Hoechst-Roussel Pharmaceuticals Inc. | 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines |
ES2233671T3 (es) * | 2000-08-08 | 2005-06-16 | Sanofi-Aventis | Derivados de benzimidazol, su preparacion y aplicacion en terapeutica. |
AU2002358650A1 (en) | 2001-12-14 | 2003-06-30 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
WO2003104233A1 (en) * | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors |
US20070032469A1 (en) | 2005-08-05 | 2007-02-08 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
KR20080049130A (ko) * | 2005-09-30 | 2008-06-03 | 아스트라제네카 아베 | 세포 증식 억제 활성을 갖는 이미다조 [1,2-a] 피리딘 |
US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
MX2013008822A (es) * | 2011-02-09 | 2013-10-07 | Hoffmann La Roche | Compuestos heterociclicos como inhibidores de cinasa fosfatidilinositol-3 (pi3). |
-
2012
- 2012-11-08 GB GBGB1220157.0A patent/GB201220157D0/en not_active Ceased
-
2013
- 2013-11-07 ES ES13786679.4T patent/ES2628046T3/es active Active
- 2013-11-07 RS RS20170565A patent/RS56056B1/sr unknown
- 2013-11-07 SI SI201330669T patent/SI2917217T1/sl unknown
- 2013-11-07 DK DK13786679.4T patent/DK2917217T3/en active
- 2013-11-07 EP EP13786679.4A patent/EP2917217B1/en active Active
- 2013-11-07 HU HUE13786679A patent/HUE033485T2/en unknown
- 2013-11-07 PT PT137866794T patent/PT2917217T/pt unknown
- 2013-11-07 KR KR1020157014733A patent/KR101812390B1/ko active IP Right Grant
- 2013-11-07 LT LTEP13786679.4T patent/LT2917217T/lt unknown
- 2013-11-07 US US14/441,785 patent/US9745299B2/en active Active
- 2013-11-07 CA CA2890643A patent/CA2890643C/en active Active
- 2013-11-07 PL PL13786679T patent/PL2917217T3/pl unknown
- 2013-11-07 AU AU2013343550A patent/AU2013343550B2/en active Active
- 2013-11-07 CN CN201380064124.XA patent/CN104903321B/zh active Active
- 2013-11-07 MX MX2015005772A patent/MX363609B/es unknown
- 2013-11-07 BR BR112015010019-8A patent/BR112015010019B1/pt active IP Right Grant
- 2013-11-07 WO PCT/EP2013/073311 patent/WO2014072435A1/en active Application Filing
- 2013-11-07 JP JP2015541140A patent/JP6101812B2/ja active Active
-
2015
- 2015-05-07 IL IL238693A patent/IL238693A0/en active IP Right Grant
-
2017
- 2017-05-29 HR HRP20170802TT patent/HRP20170802T1/hr unknown
- 2017-06-06 CY CY20171100592T patent/CY1119084T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US9745299B2 (en) | 2017-08-29 |
SI2917217T1 (sl) | 2017-08-31 |
BR112015010019A8 (pt) | 2019-09-17 |
HUE033485T2 (en) | 2017-12-28 |
KR20150091074A (ko) | 2015-08-07 |
CY1119084T1 (el) | 2018-01-10 |
MX363609B (es) | 2019-03-28 |
CN104903321B (zh) | 2017-10-24 |
JP6101812B2 (ja) | 2017-03-22 |
AU2013343550B2 (en) | 2016-09-22 |
IL238693A0 (en) | 2015-06-30 |
MX2015005772A (es) | 2015-11-18 |
LT2917217T (lt) | 2017-07-25 |
BR112015010019B1 (pt) | 2022-08-09 |
EP2917217A1 (en) | 2015-09-16 |
PT2917217T (pt) | 2017-06-07 |
AU2013343550A1 (en) | 2015-05-14 |
KR101812390B1 (ko) | 2017-12-26 |
US20150274726A1 (en) | 2015-10-01 |
PL2917217T3 (pl) | 2017-10-31 |
CA2890643C (en) | 2018-05-22 |
GB201220157D0 (en) | 2012-12-26 |
JP2016503408A (ja) | 2016-02-04 |
EP2917217B1 (en) | 2017-03-08 |
CA2890643A1 (en) | 2014-05-15 |
WO2014072435A1 (en) | 2014-05-15 |
ES2628046T3 (es) | 2017-08-01 |
CN104903321A (zh) | 2015-09-09 |
HRP20170802T1 (hr) | 2017-08-11 |
RS56056B1 (sr) | 2017-09-29 |
DK2917217T3 (en) | 2017-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015010019A2 (pt) | benzimidazóis tricíclicos substituídos | |
CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
CY1119714T1 (el) | Ενωσεις αναστολεων | |
CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
CY1120692T1 (el) | Καινοφανη παραγωγα βενζιμιδαζολης ως αναστολεις κινασων | |
CY1118771T1 (el) | Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων | |
UY38712A (es) | Lactamas fusionadas de arilo y heteroarilo | |
CR20150368A (es) | Inhibidores de histona desmetilasa | |
EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
PH12015500627A1 (en) | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives | |
CY1117147T1 (el) | Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2 | |
CL2015001508A1 (es) | Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros. | |
TR201819653T4 (tr) | Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik. | |
EA201490919A1 (ru) | Производные бетулина | |
CY1116007T1 (el) | Ενωση ιμιδαζο[4,5-c]κινολιν-2-ονης και χρηση της ως διπλος αναστολεας της ρ13 κινασης/mtor | |
CR20140525A (es) | Compuestos de N-alquiltriazol como antagonistas de LPAR | |
BR112015005243A2 (pt) | métodos para o tratamento de câncer de mama localmente avançado | |
EA201590962A1 (ru) | Новые соединения | |
GT201500071A (es) | Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3 | |
EA201591024A1 (ru) | Димерные соединения | |
EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
EA201591939A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРА CB2 | |
CY1118645T1 (el) | Χρηση pidotimod στη θεραπεια της ψωριασης | |
EA201690797A1 (ru) | Новые соединения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.1 NA RPI NO 2678 DE 03/05/2022 POR TER SIDO INDEVIDA. |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2013, OBSERVADAS AS CONDICOES LEGAIS |